Jul 6, 2022

ST PHARM Announces HIV-1 / AIDS Treatment Drug 'STP0404' Phase 1 Clinical Trial Results 'Positive and Safe'

- ST Pharm emphasized that the highest dose did not cause any significant side effects and found no maximum tolerated dose (MTD) during the study.

- ST Pharm plans to announce the results of the phase 1 study of STP0404 at the 24th International AIDS Conference to be held in Montreal, Canada, from July 29 to Aug. 2.

- ST Pharm is conducting joint research with Emory University and Colorado State University to find a cure for AIDS. The U.S. National Institutes of Health selected STP0404 as its research support project in May 2018.